All In Biotech

Drug Trial Radar · NCT02101866

A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers

A Randomized, Single-Center, Open-Label, Two-Period, Two-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Product Formulations in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: May 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Mar 2014

Primary completion

May 2014

Study completion Jun 2014

Sponsor

Lead sponsor
Biota Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study aims to determine the oral bioavailability of a single dose of a new vapendavir tablet formulation and compare it to that of the previous vapendavir capsule formulation. The safety of both drug products will also be assessed.

Conditions

  • Healthy

Interventions

  • Vapendavir 300 mg tabletDrug

    tablet - single dose

  • Vapendavir 132 mg capsulesDrug

    2 capsules - single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Systemic exposure profile of a single dose of a vapendavir 300 mg tablet compared to the exposure profile following a single dose of two 132 mg vapendavir capsulesTime frame: maximum up to 46 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigative Site

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.